about
"No Zinc deficiency but a putative immunosuppressive role for labile Zn in patients with systemic autoimmune disease".Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociRheumatoid factor by laser nephelometry and Waaler-Rose assay: prognostic value in patients with recent-onset rheumatoid arthritis.Thrombopoietin levels in systemic lupus erythematosus are linked to inflammatory cytokines, but unrelated to thrombocytopenia or thrombosis.Single-photon-emission computed tomography of the brain in the evaluation of cerebral lupus.Systemic lupus erythematosus. III. Observations on clinical renal involvement and follow up of renal function: Dutch experience with 110 patients studied prospectively.Increased mortality in ankylosing spondylitis is related to disease activity.Pancytopenia in systemic lupus erythematosus related to azathioprine.Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patientsLow copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis.Asymptomatic hyperuricemia is not an independent risk factor for cardiovascular events or overall mortality in the general population of the Busselton Health Study.Rheumatoid factors do not predict cardiovascular disease and mortality in the general population in the Busselton Health Survey.Pure red-cell aplasia in systemic lupus erythematosus.Susceptibility for Lupus Nephritis by Low Copy Number of the FCGR3B Gene Is Linked to Increased Levels of Pathogenic Autoantibodies.CD4 cell count and CD4/CD8 ratio increase during rituximab maintenance in granulomatosis with polyangiitis patientsIL-17A levels in systemic lupus erythematosus associated with inflammatory markers and lower rates of malignancy and heart damage: Evidence for a dual role.Dramatic response to IL1-RA treatment in longstanding multidrug resistant Schnitzler's syndrome: a case report and literature review.Recurrent podocytopathy in a patient with systemic lupus erythematosus.Should rheumatoid factor in rheumatoid arthritis be sent to Davy Jones's Locker?Characteristics of late onset neutropenia in rheumatologic patients treated with rituximab: a case review analysis from a single center.Successful treatment with bortezomib in type-1 cryoglobulinemic vasculitis patient after rituximab failure: a case report and literature review.Should Pneumocystis jiroveci prophylaxis be recommended with Rituximab treatment in ANCA-associated vasculitis?Epidemiology of spondyloarthritis: a review.Renal histology in Indigenous Australians with lupus nephritis.Frequency, presentation, and outcome of Takayasu arteritis in Western Australia.Risk of mortality in patients with giant cell arteritis: A systematic review and meta-analysis.Increased von Willebrand factor levels in patients with systemic lupus erythematosus reflect inflammation rather than increased propensity for platelet activation.The influence of ERAP1 gene variants on clinical phenotype in ankylosing spondylitis.[When the obvious is not the common].Staphylococcus Aureus carriage and long-term Rituximab treatment for Granulomatosis with polyangiitis.SLICC/ACR Damage Index in Afro-Caribbean patients with systemic lupus erythematosus: changes in and relationship to disease activity, corticosteroid therapy, and prognosis.Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.Effect of continuous normalization of serum complement levels on clinically evident lupus nephritis.The distribution of HLA-B27 subtype in patients with ankylosing spondylitis in Northern Norway.Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.Clinical renal involvement in Afro-Caribbean lupus patients.Current causes of death in systemic lupus erythematosus in Europe, 2000--2004: relation to disease activity and damage accrual.B-lymphocyte activating factor levels are increased in patients with Wegener's granulomatosis and inversely correlated with ANCA titer.Tumor necrosis factor-α promoter -308/238 polymorphism association with less severe disease in ankylosing spondylitis is unrelated to serum TNF-α and does not predict TNF inhibitor response.
P50
Q30380619-16228254-C0B9-4B3C-AA75-4645E1A23605Q30417517-58F10E65-C1DD-4C8B-9B8A-4155F9D4DFD3Q33224257-5A4B7A2D-65D6-4F93-B550-26AA625FC8B7Q33417017-80F0909C-3DB6-4020-B763-6313B9346BD8Q33470628-B9595B24-7E34-4FB9-B5A3-145F2A70DCDDQ33562068-FCA2484A-4C10-4585-AAE8-A2F924DFBF54Q34203097-86AC7A83-D144-4D19-97FF-9C6F622C66D7Q34418460-3C89EF47-CD5D-46E5-8573-1ADD13721AE8Q35645174-F5DE1FE9-4F45-491D-AFB3-0C72568B625AQ35842117-DCEF6F7D-BC97-4B03-A327-32628A4F0017Q36084997-B1DCD2C7-6570-4D44-8666-72D1E2CC92FCQ36225590-07C7533E-D817-4990-8853-B7EF757AAB5CQ36383052-AC3DB2DF-BB19-4D31-8218-8EAACB789AE3Q36442498-154D4071-2038-451F-A5BF-7633E9AE79F2Q36995390-BB75303B-982E-48E8-94A6-6F6CB0B32221Q37282164-33A4F39D-7B39-457D-93BB-FC5AC39E0BCDQ37679294-66711FC0-DF73-4973-B66E-E1C75349EC7DQ37684873-F14EF9B1-5F55-4B9D-9118-B730151D8BDBQ37695735-44B67A4E-B707-4FFD-9393-BB989F59DEA5Q37972622-15BD7A44-5B54-42D0-83AA-47D18ED8D117Q37981041-6DBBAEE9-94E4-4231-ABA9-337A5364C565Q38101526-BCE5AA44-2206-429B-9CA4-2040C6DB5C83Q38113507-B1052BBE-2BC9-46F2-B540-B76E41377EC4Q38124275-3D2C9D5B-B28F-4A0B-ABC0-5354A021E9D9Q38649705-AA91C1A4-C3D4-4995-BC43-08CB5BE9DCADQ38871347-FA25390E-BF34-4D52-A019-1ADAA3599458Q39046881-15233F09-33D7-4DBC-822F-30E8F0945BF3Q39367860-660E6FC8-A122-414F-8902-D7EB697A18E2Q39838349-0D798208-7595-4FFD-B418-8E272DE27548Q40373357-4C60DE17-80EF-4200-A3D2-780595EC004BQ41126772-894B85E8-1083-45A4-BA2F-00A3A0D706DAQ41748151-76604522-0382-4879-934C-1DCAAA375B69Q43416268-45E0A29C-871E-488D-9991-7538F447EDE7Q43450070-B15F863B-FC5D-4FA6-ACF7-95A3CDFCF0FFQ44263137-4C832CB3-A2A3-4100-8EAF-DEBE4DBDF255Q44267146-89947E1D-B9AC-4339-8830-B342D1A0BBE9Q44590237-D4279B7B-A7F8-4D3D-9019-648E0A028CB8Q44699349-25E65B0E-55A7-4704-BE56-27A7A2F2C0B1Q45331351-C3F61BFF-34B8-4742-88F1-9A4D7E720131Q45913031-490C2338-4302-426A-AF40-0A581B58297A
P50
subject
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Johannes C Nossent
@ast
Johannes C Nossent
@en
Johannes C Nossent
@es
Johannes C Nossent
@nl
Johannes C Nossent
@sl
type
label
Johannes C Nossent
@ast
Johannes C Nossent
@en
Johannes C Nossent
@es
Johannes C Nossent
@nl
Johannes C Nossent
@sl
altLabel
Hans Nossent
@en
prefLabel
Johannes C Nossent
@ast
Johannes C Nossent
@en
Johannes C Nossent
@es
Johannes C Nossent
@nl
Johannes C Nossent
@sl
P1006
P214
P1006
P106
P21
P214
P31
P496
0000-0002-2833-7997
P735
P7859
viaf-236314672